Sinopharm Tech Holdings Limited
國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

ANNOUNCEMENT
MADE PURSUANT TO RULE 17.50(2)(L) AND RULE 17.50A(2) OF THE GEM LISTING RULES

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Sinopharm Tech Holdings Limited (the "**Company**", together with its subsidiaries as the "**Group**") pursuant to Rule 17.50(2)(l) and Rule 17.50A(2) of the Rules Governing the Listing of Securities on GEM (the "**GEM Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board has been notified by Mr. Lau Fai Lawrence ("**Mr. Lau**"), an independent non-executive Director of the Company and an independent non-executive director of Titan Petrochemicals Group Limited (In Liquidation) ("**Titan**") (Stock Code: 1192), that on 20 September 2019, Sino Charm International Limited served a winding up petition to the Supreme Court of Bermuda (the "**Bermuda Court**") for an order that Titan be wound up by the Bermuda Court (the "**Winding Up Petition**"). On hearing the Winding Up Petition on 12 July 2021 and 13 July 2021, the Bermuda Court issued a judgment in relation to the Winding Up Petition (the "**Judgment**") and consequently an order was granted by the Bermuda Court on 11 August 2021 (the "**Order**") that Titan be wound up and PricewaterhouseCoopers Limited in Hong Kong and PricewaterhouseCoopers Advisory Limited in Bermuda, be appointed as joint provisional liquidators of Titan. Please refer to the announcements issued by Titan dated 13 August 2021 and 31 August 2021 for further information in relation to the winding up proceedings, the Judgment and the Order.

Titan is a company incorporated in the Bermuda with limited liability and, together with its subsidiaries, are principally engaged in the business of shipbuilding, ship-repairing, manufacturing of steel structure and the trading of bulk commodities. The securities of Titan are listed on the Main Board of the Stock Exchange and have been suspended from 1 April 2021 and up to the date of this announcement. According to Mr. Lau, he is not a party to such winding up proceedings and is not aware of any current or potential claim that has been or will be made against him as a result of such proceedings.

This announcement is made by the Company to report the change of information in relation to Mr. Lau in compliance with the requirements of Rule 17.50A(2) of the GEM Listing Rules. Mr. Lau has confirmed to the Company that save as disclosed in this announcement, there is no other information relating to him that is required to be disclosed pursuant to the requirements of Rules 17.50(2)(h) to 17.50(2)(v) of the GEM Listing Rules and he is not aware of any other matters that need to be brought to the attention of the shareholders of the Company.

The Board has no further information on the abovementioned matter other than those set out above which is based on the information supplied by Mr. Lau and the announcements made by Titan dated 13 August 2021 and 31 August 2021. To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, neither Titan nor its subsidiaries are in any way related to the Group. The Board is not in a position to express any opinion on the matters relating to Titan's winding up proceedings. As the above matter did not involve the Group, the Board is of the opinion that such matter has or will have no adverse effect on the business and operations of the Group. Taking into accounts of the background, expertise, skills, experience and independence of Mr. Lau, the Board considers that it would be suitable for Mr. Lau to remain as an independent non-executive Director.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 10 September 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not *misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

This announcement will remain on the "Latest Listed Company Information" page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.